z-logo
open-access-imgOpen Access
Immunity drives TET1 regulation in cancer through NF-κB
Author(s) -
Évelyne Collig,
Annalisa Canale,
Clémence Al Wardi,
Martin Bizet,
Emilie Calonne,
Sarah Dedeurwaerder,
Soizic Garaud,
Céline Naveaux,
Whitney Barham,
Andrew J. Wilson,
Sophie Bouchat,
Pascale Hubert,
Carine Van Lint,
Fiona E. Yull,
Christos Sotiriou,
Karen WillardGallo,
Agnès Noël,
François Fuks
Publication year - 2018
Publication title -
science advances
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.928
H-Index - 146
ISSN - 2375-2548
DOI - 10.1126/sciadv.aap7309
Subject(s) - epigenetics , immune system , immunity , nf κb , cancer research , cancer , biology , computational biology , microbiology and biotechnology , immunology , genetics , gene , signal transduction
Ten-eleven translocation enzymes (TET1, TET2, and TET3), which induce DNA demethylation and gene regulation by converting 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), are often down-regulated in cancer. We uncover, in basal-like breast cancer (BLBC), genome-wide 5hmC changes related to regulation. We further demonstrate that repression is associated with high expression of immune markers and high infiltration by immune cells. We identify in BLBC tissues an anticorrelation between expression and the major immunoregulator family nuclear factor κB (NF-κB). In vitro and in mice, is down-regulated in breast cancer cells upon NF-κB activation through binding of p65 to its consensus sequence in the promoter. We lastly show that these findings extend to other cancer types, including melanoma, lung, and thyroid cancers. Together, our data suggest a novel mode of regulation for in cancer and highlight a new paradigm in which the immune system can influence cancer cell epigenetics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom